BONESUPPORT’s CERAMENT G used in First U.S. Cases

BONESUPPORT’s antibiotic-eluting bone graft CERAMENT G (Gentamicin) has been used surgically for the first time in patients in the U.S. The patients treated had bone infection caused by fractures induced by trauma.

BONESUPPORT received authorization for CERAMENT G in the management of osteomyelitis from FDA earlier this year. The extensive clinical documentation on which the market approval is based, shows that CERAMENT G reduces the risk of recurrent bone infection to 4.3% to 5.5% versus 13.3% for the current U.S. standard of care, which is PMMA-beads. CERAMENT G is reported to be the first and only FDA-authorized combination antibiotic eluting bone graft.

BONESUPPORT’s CERAMENT G is an implantable device/drug combination bone void filler that provides a pathway for a one-stage approach to the management of bone infection with its dual mode of action that delivers bone remodeling with reliable and safe local elution of a broad-spectrum antibiotic.

Source: BONESUPPORT